Latest / Applied Clinical Trials
ACT Brief: De-Identified RWE Gains Ground, HHS Funding Stabilizes Research, and U.S. Finalizes WHO Exit
In today’s ACT Brief, we look at how FDA policy is accelerating the use of de-identified real-world evidence in clinical development, why a new bipartisan funding package could stabilize federal research agencies, and how the US withdrawal from the World Health Organization reshapes global health coordination.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.